Protagonist Therapeutics, Inc. cash flow to debt ratio of 558.67% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Protagonist Therapeutics, Inc.'s free cash flow has decreased 69.32% from $182.80M last year to $56.08M, signaling decreasing performance

Protagonist Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Protagonist Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.02 last year to 0.01 today, signaling strengthened financials

Protagonist Therapeutics, Inc. has a net cash position, so leverage is healthy.

Protagonist Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Protagonist Therapeutics, Inc.'s profit margin has decreased (53.58%) in the last year from 63.34% to 29.40%, signaling decreasing performance

Protagonist Therapeutics, Inc.'s short-term assets of $577.57M exceed its short-term liabilities of $45.44M

Protagonist Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Protagonist Therapeutics, Inc.'s return on equity of 12.03%, is lower than 15.00%, indicating bad performance

Protagonist Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Protagonist Therapeutics, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Protagonist Therapeutics, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Protagonist Therapeutics, Inc. has a free cash flow yield of 0.58%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Protagonist Therapeutics, Inc.'s yearly earnings has decreased 147.29% since last year from $275.19M to $-130.15M, signaling decreasing performance

Protagonist Therapeutics, Inc.'s yearly revenue has decreased 89.41% since last year from $434.43M to $46.02M, signaling decreasing performance

ROIC 6.74% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Protagonist Therapeutics, Inc.'s 3-year revenue CAGR of 20.07% is positive, indicating growing revenue over the past 3 years

Protagonist Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Protagonist Therapeutics, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Protagonist Therapeutics, Inc. has insufficient data to evaluate this check.

Protagonist Therapeutics, Inc. has an earnings yield of 0.84%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Protagonist Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Protagonist Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Protagonist Therapeutics, Inc. is overvalued relative to its fair value price of -48.14 based on Earnings Fair Value model

Protagonist Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Protagonist Therapeutics, Inc. has a price-to-book ratio of 11.75x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Protagonist Therapeutics, Inc. has a price-to-sales ratio of 35.07x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue